Clinical Trials
22 trialsNCT02914405 2026-04-28
MiniVan
University Hospital Southampton NHS Foundation Trust
Phase 1 Active not recruiting
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT00199862 2025-07-04
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT07008703 2025-06-06
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1/2 Recruiting
NCT06061276 2024-09-23
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Sun Yat-sen University
Phase NA Recruiting
NCT06070636 2024-08-09
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00033293 2023-04-18
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT05259397 2023-03-08
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Pfizer
Phase 1 Withdrawn
NCT02707588 2023-02-28
PembroRad
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02410512 2022-04-01
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT02367794 2022-03-21
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Hoffmann-La Roche
Phase 3 Completed
NCT02458638 2021-06-04
A Study of Atezolizumab in Advanced Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT01765790 2021-05-05
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Takeda
Phase 1 Completed
NCT00145626 2017-06-19
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00145613 2009-02-13
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00143559 2009-01-29
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00152139 2009-01-29
Stem Cell Transplantation for Patients With Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00186823 2009-01-29
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 3 Completed